Quarterly report pursuant to Section 13 or 15(d)

DERIVATIVE LIABILITY (Details Narrative)

v3.22.2.2
DERIVATIVE LIABILITY (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Jul. 28, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Gain (Loss) on Sale of Derivatives $ 0 $ 472,143 $ 0 $ 670,143    
Loan Agreement [Member] | K2 HealthVentures LLC [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Secured debt $ 21,190,000   21,190,000     $ 50,000,000
Initial measurement of fair value     133,710   $ 133,710  
Gain (Loss) on Sale of Derivatives     $ 0      
Loan Agreement [Member] | K2 HealthVentures LLC [Member] | Share-based Payment Arrangement, Tranche One [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Secured debt           $ 20,000,000